Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": The CASA randomized trial 
Introduction
The appropriate use of adjuvant chemotherapy for elderly (>70) women with breast carcinoma remains controversial. 1 A common reason for not offering chemotherapy is the concern for excessive toxicity in older, frail patients. Several studies have demonstrated decreasing use of chemotherapy with increasing age. 2 Only 3394 women were in the age range 60e69 and only 307 patients were over 70 years in the 1998 chemotherapy overview conducted by the Early Breast Cancer Trialists' Collaborative Group, so no conclusions could be drawn on the utility of chemotherapy for the older group of patients. 3 A recently published study from Cancer and Leukemia Group B (CALGB) in patients older than 65 years showed the superiority of a standard adjuvant chemotherapy, compared with capecitabine, in women with hormone receptor-negative tumors evaluated in a retrospective sub-analysis, 4 however no clinical trials have been conducted specifically in elderly women with endocrine nonresponsive early breast cancer or with co-morbidities that may make a treating oncologist hesitant to prescribe standard chemotherapy.
As only about 15% of women 65 years and older present with ER and PR-negative tumors, this subpopulation is under-represented in trials and even overviews of trials. Thus, a therapeutic dilemma exists. Breast cancer relapses occur earlier in this population compared to those with hormone receptor-expressing tumors, even when axillary nodes are negative. Reducing the risk of relapse for women whose life expectancy is less than ten years and who have co-morbidities that make "standard chemotherapy" inappropriate should be an area of continued research, whereas biologically (and functionally) fit patients can be successfully treated as younger postmenopausal women. 5 The Chemotherapy Adjuvant Study for women at advanced Age (CASA) trial was designed to test whether pegylated liposomal doxorubicin (PLD, Caelyx Ò , Doxil Ò ) or low dose, metronomic cyclophosphamide and methotrexate (CM) might be better tolerated within a patient subpopulation frailer than those usually included in breast cancer clinical trials.
Materials and methods

Study design
CASA is a multi-national, phase III randomized clinical trial conducted by the International Breast Cancer Study Group (IBCSG 32-05) within the Breast International Group (BIG 1-05) for older women aged 66 years with operable, endocrine nonresponsive (ER < 10%; and PgR < 10%) breast cancer. Other eligibility criteria included performance status (ECOG) 0e2; no metastatic disease; surgery for primary breast cancer with negative margins for invasive breast cancer and DCIS; adequate bone marrow, renal (calculated creatinine clearance 50 mL/min), hepatic and cardiovascular function. Geriatric and cognitive assessments were obtained and scored prior to randomization.
The trial was open for accrual between November 2005 and December 2007. The design allowed for two options: 1) patients who were candidates to receive no adjuvant therapy (CASA-nil) and 2) patients considered to require some adjuvant treatment (CASA-CM) (Fig. 1) . The primary objective of CASA was to investigate the efficacy of PLD as adjuvant chemotherapy. Secondary objectives included tolerability (treatment completion), adverse events (AEs), and quality of life (QL). AEs were collected during and after chemotherapy.
The study was approved by the local ethics committees and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent. Schering-Plough provided study drug and funding at the start of the trial, but withdrew support when accrual milestones were not met. The protocol allowed trastuzumab for one year after chemotherapy (PLD or CM) for patients with HER2-positive tumors, following a cardiac evaluation.
Treatments and follow-up
The duration of both regimens was 16 weeks. The PLD regimen was delivered every 2 weeks at 20 mg/m 2 iv. 6 This schedule was developed from the experience in AIDS-associated Kaposi patients, and was considered safer for an elderly population with co-morbid diseases. The metronomic CM was given orally, cyclophosphamide 50 mg/day continuously and methotrexate 2.5 mg/twice daily days 1 and 4 of every week. The CM regimen 7 was developed in advanced disease and resulted in tumor shrinkage even in heavily pretreated patients. Follow-up was planned every three months for the first year, every six months for years 2e5, and yearly thereafter. ECG and echocardiogram were performed at baseline, at the end of adjuvant treatment (month 6 after randomization), and whenever clinically indicated.
Quality of life assessment
To evaluate short and medium-term treatment effects on QL (PLD versus non-PLD), a longitudinal design was used, with assessments required at baseline (prior to randomization), 3, 6 and 12 months after randomization. The QL assessment included three components: 1) self-reported QL with Linear Analogue SelfAssessment (LASA) indicators (range 0e100) for physical wellbeing, mood, 8 
Statistical analysis
The primary endpoint was breast cancer-free interval (BCFI), defined as the time from randomization to any of following events: invasive breast cancer recurrence at local, regional, or distant sites; a new invasive cancer in the contralateral breast. Second (nonbreast) malignancies were ignored and deaths without cancer event were censored at the time of death. In the absence of a BCFI event, BCFI was censored at last follow-up visit. Secondary endpoints included tolerability (treatment completion), AEs, and QL. The trial was designed to achieve an 80% power to detect a 30% reduction in the risk of a breast cancer event (hazard ratio ¼ 0.70; improvement in 5-year BFCI from 65% in the non-PLD group to 74% in the PLD group) using an overall two-sided 0.05 level test of significance. A total of 258 breast cancer events were required and the planned sample size was 1296 patients.
Because only 6% of the targeted sample was enrolled to the study, no formal statistical comparisons were performed. Toxicities were assessed using the NCI CTCAE version 3.0.
15 Toxicity summaries considered all patients who received study treatment. The Kaplane Meier method 16 was used to estimate BCFI and the corresponding rates at 3 years with 95% confidence intervals (CIs). Table 1 displays the characteristics of the 77 patients enrolled. After review, 14 (18%) of the 77 patients were considered ineligible primarily due to low creatinine clearance (<45 ml/min for 11 patients). While most patients were ambulatory (performance status 0 for 76%), 79% reported at least one other medical condition and 83% were receiving regular medications at study entry. Based on local assessment, 71% of patients had HER2-negative disease (thus triple-negative), and most tumors were classified as ER and PgR-absent (81% and 88%, respectively). Five patients (6%, 2 PLD, 3 nil) were randomized within Option 1 (CASA-nil) and 72 (94%, 36 PLD, 36 CM) were randomized within Option 2 (CASA-CM). Therefore, among the 77 enrolled patients, 38 were randomized to receive PLD and 39 a non-PLD regimen (CM or nil). 
Results
Patient characteristics
Co-morbidities at baseline
The most common co-morbidity at baseline was hypertension, reported in 64% of all enrolled patients (63% PLD and 65% non-PLD). Less frequent co-morbidities included osteoporosis (17%), endocrine-metabolic conditions (17%), and cardiac arrhythmia (16%). A history of smoking was reported in 22% and 17% were receiving cholesterol-lowering medications. Table 2 summarizes the AEs reported during the treatment period. Among the 72 patients who started treatment, 70 (97%) patients reported experiencing some type of AEs. Nineteen (51%) on PLD group and 12 (34%) on CM group experienced grade 3 AEs. The most common grade 3 AEs were hand-foot skin reaction on PLD (8 cases) and hypertension on CM (7 cases). No grade 4 or above AEs were reported during treatment.
Adverse events
Adverse events were also reported after treatment completion. Among the 71 patients with follow-up forms available, 35 (49%) reported experiencing one or more AEs of any grade. Fifteen patients (42%) on PLD and 12 (34%) on CM experienced grade 3 as the highest grade AEs, the most common being hypertension. Four patients (one PLD, three CM) reported grade 4 as the highest grade AE: infection, thrombosis/thrombus/embolism, constipation, and infection, respectively. Three patients randomized to PLD died from non-breast cancer related causes. A 73 year old died of pulmonary fibrosis 4.5 months after randomization and 8 courses of treatment, a 73 year old died of cerebrovascular ischemia 27 months after randomization and 7 courses of treatment, and a 74 year old who did not start PLD died from unknown cause 14 months after randomization. There were no reports of congestive heart failure or other cardiac toxicities (data not shown). One patient experienced hematologic AEs requiring treatment modification or delay during Table 2 Adverse events reported during chemotherapy according to grade. week 15e16, when WBC count reached 2.8 and neutrophil count 1.4, whereas no patients reported febrile neutropenia while on chemotherapy. Of the 21 HER2-positive, six received trastuzumab after the completion of chemotherapy, 3 after CM and 3 after PLD. None of these patients experienced cardiac side effects after these treatments.
Outcomes
The median follow-up was 42 months, and 19% (15 of 77) of patients had a BCFI event. The KaplaneMeier estimate of the BCFI probabilities at 3 years were similar for the PLD (0.78 (95% CI: 0.65e 0.94)) and the non-PLD groups (0.78 (95% CI: 0.68e0.93)).
Quality of life
Patients on PLD reported worse QL scores than those on non-PLD for all measures (except nausea/vomiting) at most postbaseline time points. Fig. 2 shows the mean and 95% CI for selected QL scores (i.e. physical well-being, functional performance, overall disease/treatment burden, mucosa inflammation of the mouth) at each assessment. Similarly, patients receiving PLD indicated worse cognitive and physical functioning (Fig. 2) . Overall, the proportion of patients that had impairment in cognitive function was higher at baseline (18%; 13/73) than at 12 months (8%; 5/ 61). Among 59 patients with assessments at both baseline and 12 months, impairment in cognitive function was reported for 10 (17%) at baseline and 5 (8%) at 12 months. Between 15% (baseline; 11/73) and 26% (month 12; 16/62) of patients met the cutoff for being physically vulnerable.
Discussion
The issue of chemotherapy for elderly women with early breast cancer continues to be a challenge. The CASA trial was specifically designed for older women with endocrine nonresponsive tumors, not suitable for "standard chemotherapy regimens" due to comorbidities, age or frailty. This "niche trial" required a worldwide effort and a strictly defined population of only endocrine nonresponsive disease, thus avoiding a dilution of the potential magnitude of chemotherapy effect size by including endocrine responsive patients less likely to benefit from chemotherapy.
Recent reports reinforce the importance of selecting treatment according to tumor biology, 17e20 and even effective drugs like taxanes may be of less value for patients with HER 2-negative, hormone receptor-positive disease, 20 who usually represent most of older patients seen.
A recent review paper 21 summarized five major randomized clinical trials designed to answer important questions in elderly patients, an increasing population of patients with breast cancer. The German Breast Group trial (ICE) completed the accrual of patients randomized to ibandronate or the combination of ibandronate and 6 cycles of capecitabine in August 2008 (http:// clinicaltrials.gov/show/NCT00196859). A total of 1409 patients older than 64 years of age with all tumor subtypes were recruited but no outcome data are available, although early presentations of side effects and quality of life showed no safety concerns in both arms in the first 100 patients treated.
22,23
The CALGB trial was recently published by Muss et al. 4 This noninferiority trial evaluated a standard regimen, such as anthracycline and cyclophosphamide or cyclophosphamide-methotrexate-5-fluorouracil (CMF), as compared with capecitabine given as a single agent for the same period of time. In the overall population there was a statistically significant advantage for standard regimens over capecitabine, which appeared to be driven primarily by the results for the endocrine nonresponsive subpopulation. Little difference in disease-free or overall survival between the arms was seen in the receptor-positive subgroup. The trial unfortunately did not include a regimen of hormone therapy alone. This trial does not further our knowledge of how best to treat patients with hormone receptornegative tumors that are not suitable for a standard regimen. An ongoing trial for the elderly population (ELDA Trial) is being conducted by investigators in Naples (ClinicalTrials.gov: NCT00331097). This study randomizes patients with node positive or high risk node negative tumors to classical CMF or weekly taxotere. Safety results were published by Nuzzo et al. 24 reporting the feasibility of the trial and confirming a higher rate of toxic effects with the CMF regimen as originally reported more than 10 years ago by the International Breast Cancer Study Group. 25 A recently published update of EUSOMA/SIOG guidelines reaffirms that patients with hormone receptor-negative disease 26 would derive the largest benefit from chemotherapy. As the tolerance of cancer treatment and life expectancy for elderly women with early breast cancer is limited, the effect of treatment on QL is of particular importance in this patient population. The chemotherapy regimens selected for the CASA trial were not previously tested in adjuvant studies. Both are characterized by a metronomic schedule, and clinical experience in advanced disease showed that they are feasible and active treatments even in pretreatedmetastatic breast cancer, representing an alternative to classical anthracycline or more aggressive therapy, particularly in vulnerable, frail patients. 6, 7 As expected skin toxicity was prevalent in the PLD group; one partial explanation could be that age 27 and treatment schedule 28 are known to interfere with the PLD clearance. Patients receiving PLD in this study indicated worse QL (except for nausea/ vomiting), cognitive and physical functioning than those receiving a non-PLD regimen. The proportion of women with impaired cognition decreased from baseline to the 12 month assessment. It is unclear whether this observation indicates a real time trend, or is merely a reflection of better cognition among women with data at the 12 month assessment. In a prospective cohort study of older women with breast cancer after their diagnosis, 29 impaired physical functioning and mental health three months after surgery proved to be predictors of poorer self-perceived health and psychosocial adjustment one year after surgery. This suggests that impairment to QL early in the treatment course seems to play a more important role for subsequent QL than age and treatment. Despite a multi-national effort and adequate funding at study initiation, the CASA trial was not able to reach its accrual target at a rate satisfactory to our pharmaceutical funding partner. The inability to meet the trial accrual goal is most likely related to several factors. Ethical Committees were concerned about a lack of efficacy data for the regimens (PLD and CM) in elderly breast cancer patients and for those with HER2-positive disease also receiving Herceptin. There was also concern that metronomic CM might not be an effective regimen even though it had been evaluated 30, 31 and was attractive for use in elderly patients because it was given at doses low enough to avoid myelo-suppression and other doselimiting side effects. The low enrollment (5 of 77) in option 1 PLD vs. nil) reflects the difficulty associated with randomizing patients in studies with a non-treatment control arm. It was difficult not only to recruit these patients but also to define the eligibility, taking into account that most 65e70 year old women are often in good physical condition and so should be treated with standard therapies. The definition of "vulnerable patients" according to the Comprehensive Geriatric Assessment (CGA) e a tool which is somewhat time-consuming e is those patients having a 4.2 fold greater risk of dying during the following two years. The VES-13 tool employed in the CASA trial is simpler but not yet widely used, and it can identify older people with increased degree of vulnerability as shown by Saliba et al. 14 and recently confirmed by Luciani et al. 32 The fact that in our trial eleven patients did not meet the eligibility criteria because of a creatinine clearance less than 45 ml/ min is of note because it represents yet another recruitment challenge. A decrease in creatinine clearance is "physiological" with increasing age as recently reported in the Renal Insufficiency and Anticancer Medications (IRMA) French national, an observational study which demonstrated high prevalence of abnormal renal function in a population of 4684 solid tumor patients; among them up to 50e60% had decreased renal function. 33 This particular comorbidity should be considered when dosing chemotherapeutic drugs that are metabolized renally and excreted. Even though randomized clinical trials represent the gold standard for establishing the efficacy of therapeutic options for cancer, their strict inclusion and exclusion criteria in the older population may limit participation and therefore the ability to make conclusions for patient care. Specific geriatric endpoints using assessments of daily living, cognitive function and preservation of independence, as recently pointed out by Muss et al. 34 should be considered for inclusion in future trials in elderly patients. Our experience with the CASA trial may be useful for planning future trials, as the questions about treating this niche population remain unanswered. Meanwhile, the population of elderly breast cancer patients is increasing dramatically along with the increasing age of the general population in USA 35 and most European countries.
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